Ii Y, Murakami E, Hiwada K
Second Department of Internal Medicine, Ehime University School of Medicine, Japan.
J Hypertens. 1991 Dec;9(12):1119-25.
We investigated the effects of the human renin inhibitor, ES-8891, and captopril on renal renin secretion and storage in the marmoset. Either ES-8891 (30 mg/kg) or captopril (2 mg/kg) was given orally twice a day for 1 week to conscious, sodium-depleted marmosets (n = 6 for each group). The ES-8891-treated group displayed a significant reduction in mean arterial pressure (MAP), plasma renin activity (PRA) and plasma immunoreactive renin (PIR) compared with the control group. Kidney renin content was significantly increased compared with the control group and enlarged renin granules containing heterogenous internum were observed in juxtaglomerular cells after treatment with ES-8891. Treatment with captopril significantly increased PRA and PIR compared with the control day as well as increasing kidney renin content and the number of renin granules with crystalline content in juxtaglomerular cells compared with the control group. These results suggest that ES-8891 inhibits both PRA and renin secretion from the kidney, resulting in an increase in renal renin storage.
我们研究了人肾素抑制剂ES - 8891和卡托普利对狨猴肾脏肾素分泌和储存的影响。将ES - 8891(30毫克/千克)或卡托普利(2毫克/千克)每日口服两次,持续1周,给药对象为清醒的、钠缺乏的狨猴(每组n = 6)。与对照组相比,ES - 8891治疗组的平均动脉压(MAP)、血浆肾素活性(PRA)和血浆免疫反应性肾素(PIR)显著降低。与对照组相比,肾脏肾素含量显著增加,并且在用ES - 8891治疗后,在球旁细胞中观察到含有异质内含物的增大的肾素颗粒。与对照日相比,卡托普利治疗显著增加了PRA和PIR,并且与对照组相比,增加了肾脏肾素含量以及球旁细胞中含有结晶内容物的肾素颗粒数量。这些结果表明,ES - 8891抑制肾脏的PRA和肾素分泌,导致肾脏肾素储存增加。